These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 18788834

  • 1. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation.
    Shen AY, Chen W, Yao JF, Brar SS, Wang X, Go AS.
    CNS Drugs; 2008; 22(10):815-25. PubMed ID: 18788834
    [Abstract] [Full Text] [Related]

  • 2. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies.
    Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW, Nasco E.
    Cerebrovasc Dis; 2000; 10(1):39-43. PubMed ID: 10629345
    [Abstract] [Full Text] [Related]

  • 3. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB, Halperin JL.
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [Abstract] [Full Text] [Related]

  • 4. Guidelines for stroke prevention in patients with atrial fibrillation.
    Howard PA.
    Drugs; 1999 Dec; 58(6):997-1009. PubMed ID: 10651387
    [Abstract] [Full Text] [Related]

  • 5. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation.
    Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W.
    J Am Coll Cardiol; 2007 Jul 24; 50(4):309-15. PubMed ID: 17659197
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
    Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM.
    Lancet; 2014 Mar 15; 383(9921):955-62. PubMed ID: 24315724
    [Abstract] [Full Text] [Related]

  • 7. Oral anticoagulants for Asian patients with atrial fibrillation.
    Sabir I, Khavandi K, Brownrigg J, Camm AJ.
    Nat Rev Cardiol; 2014 May 15; 11(5):290-303. PubMed ID: 24614113
    [Abstract] [Full Text] [Related]

  • 8. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F, Renlund H, Lip GY, Wester P, Svensson PJ, Själander A.
    JAMA Cardiol; 2016 May 01; 1(2):172-80. PubMed ID: 27437888
    [Abstract] [Full Text] [Related]

  • 9. Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.
    Essien UR, Holmes DN, Jackson LR, Fonarow GC, Mahaffey KW, Reiffel JA, Steinberg BA, Allen LA, Chan PS, Freeman JV, Blanco RG, Pieper KS, Piccini JP, Peterson ED, Singer DE.
    JAMA Cardiol; 2018 Dec 01; 3(12):1174-1182. PubMed ID: 30484833
    [Abstract] [Full Text] [Related]

  • 10. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry.
    Golwala H, Jackson LR, Simon DN, Piccini JP, Gersh B, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Thomas L, Fonarow GC, Peterson ED, Thomas KL, Outcomes Registry for Better Informed Treatment for Atrial Fibrillation (ORBIT-AF) Registry.
    Am Heart J; 2016 Apr 01; 174():29-36. PubMed ID: 26995367
    [Abstract] [Full Text] [Related]

  • 11. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.
    Adv Ther; 2012 Jun 01; 29(6):491-507. PubMed ID: 22684583
    [Abstract] [Full Text] [Related]

  • 12. Racial/Ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation.
    Shen AY, Yao JF, Brar SS, Jorgensen MB, Wang X, Chen W.
    Stroke; 2008 Oct 01; 39(10):2736-43. PubMed ID: 18635860
    [Abstract] [Full Text] [Related]

  • 13. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States.
    Baker WL, Cios DA, Sander SD, Coleman CI.
    J Manag Care Pharm; 2009 Apr 01; 15(3):244-52. PubMed ID: 19326955
    [Abstract] [Full Text] [Related]

  • 14. Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study).
    Yong C, Azarbal F, Abnousi F, Heidenreich PA, Schmitt S, Fan J, Than CT, Ullal AJ, Yang F, Phibbs CS, Frayne SM, Ho PM, Shore S, Mahaffey KW, Turakhia MP.
    Am J Cardiol; 2016 Jan 01; 117(1):61-8. PubMed ID: 26552504
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Preventing stroke in atrial fibrillation: the SPORTIF programme.
    Lip GY.
    Pathophysiol Haemost Thromb; 2005 Jan 01; 34 Suppl 1():25-30. PubMed ID: 15812201
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Secondary prevention of stroke in patients with nonvalvular atrial fibrillation: optimal intensity of anticoagulation.
    Yasaka M, Yamaguchi T.
    CNS Drugs; 2001 Jan 01; 15(8):623-31. PubMed ID: 11524034
    [Abstract] [Full Text] [Related]

  • 19. The decision to anticoagulate: assessing whether benefits outweigh the risks for patients with atrial fibrillation.
    Merli G, Weitz HH.
    Clin Cardiol; 2004 Jun 01; 27(6):313-20. PubMed ID: 15237688
    [Abstract] [Full Text] [Related]

  • 20. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis.
    Chan PH, Huang D, Yip PS, Hai J, Tse HF, Chan TM, Lip GY, Lo WK, Siu CW.
    Europace; 2016 May 01; 18(5):665-71. PubMed ID: 26504109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.